A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration

Close metadata

Recommended articles:

Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(4):40-48

Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161

Neovascular age-related macular degeneration (nAMD) causes rapid irreversible vision loss presenting a serious socio-economic problem. The recommended approach to the treatment of this pathology is the use of angiogenesis inhibitors (anti-VEGF drugs). Following the proactive principles when conducting anti-VEGF treatment helps achieve the maximum therapeutic efficacy. The evolution of diagnostic capabilities and the rising awareness of the pathogenetic features of nAMD have contributed to implementation of a more personalized approach of conducting intravitreal injections, bringing to light the necessity of determining the diagnostic criteria for repeated anti-VEGF injections. Currently, the discourse looks at the subject of OCT criteria that could act as sufficiently reliable biomarkers to help decide the change in frequency of intravitreal injections. A differentiated approach to defining the role of retinal fluid as a marker of disease activity depending on the compartment of its localization on the OCT images has not been fully determined and is of particular scientific and practical interest. The importance of correct interpretation and understanding of differences in the effects of various types of retinal fluid on the frequency of anti-VEGF injections will be discussed in this review.

Keywords:

neovascular age-related macular degeneration

subretinal fluid

intraretinal fluid

treat and extend

Authors:

Kamenskikh T.G.

Saratov State Medical University, Saratov, Russia

List of references:

Wykoff CC, Clark WL, Nielsen JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular Age-related macular degeneration. J Manag Care Spec Pharm. 2018;24(2-a Suppl):3-15. https://doi.org/10.18553/jmcp.2018.24.2-a.s3
Neroev VV. Russia’s nationwide epidemiological noninvasive study of patients with age-related macular degeneration. Rossiyskiy oftal’mologicheskiy zhurnal. 2011;2:4-9. (In Russ.)
Oftal’mologiya. Natsional’noe rukovodstvo. Pod red. Avetisova S.E., Egorova E.A., Moshetovoi L.K., Neroeva V.V., Takhchidi Kh.P. M.: GEOTAR-Media; 2008. (In Russ.)
Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Naturemedicine. 2010;16(10):1107-1111. https://doi.org/10.1038/nm1010-1107
Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Naturemedicine. 2003;9(6):669-676. https://doi.org/10.1038/nm0603-669
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug. 2007;6:273-286. https://doi.org/10.1038/nrd2115
American Academy of Ophthalmology Retina/Vitreous Panel. Preffered Practice Pattern Guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015.
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology. 2014;98(9):1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702
Klinicheskiye rekomendatsii: Vozrastnaya makulyarnaya degeneratsiya. Obshcherossiyskaya obshchestvennaya organizatsiya «Assotsiatsiya vrachey-oftal’mologov». 2017. (In Russ.). Available at: https://avo-portal.ru/doc/fkr/item/261-vozrastnaya-makulyarnaya-degeneratsiya
Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129(6):709-717. https://doi.org/10.1001/archophthalmol.2011.140
Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(2):209-213.e2. https://doi.org/10.1016/j.ajo.2011.10.016
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355:1432-1444. https://doi.org/10.1056/nejmoa062655
Rosenfeld PJ, Brown DM, Jeffrey SH, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355:1419-1431. https://doi.org/10.1056/nejmoa054481
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548. https://doi.org/10.1016/j.ophtha.2012.09.006
Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153(4):678-686. https://doi.org/10.1016/j.ajo.2011.09.013
Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122-129. https://doi.org/10.1016/j.ophtha.2012.07.042
Lanzetta P, Loewenstein A. Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259-1273. https://doi.org/10.1007/s00417-017-3647-4
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185. https://doi.org/10.1007/s10456-011-9249-6
Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceeding of the National Academy of Sciences of the USA. 2002;99(17):11393-11398. https://doi.org/10.1073/pnas.172398299
Fayzrakhmanov RR. Anti-VEGF-therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Rossiyskiy oftal’mologicheskiy zhurnal. 2019;12(2):97-105. (In Russ.) https://doi.org/10.21516/2072-0076-2019-12-2-97-105
Astakhov YuS, Nechiporenko PA. Dosing regimens of angiogenesis inhibitors in the treatment of neovascular age-related macular degeneration patients. Oftal’mologicheskiye vedomosti. 2019;12(2):47-56. (In Russ.) https://doi.org/10.17816/OV12247-56
Garcia-Layana A, Figueroa MS, Araiz J, et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging. 2015;32:797-807. https://doi.org/10.1007/s40266-015-0300-y
Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1-24. https://doi.org/10.1016/j.preteyeres.2015.07.007
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;19;364(20):1897-1908. https://doi.org/10.1056/NEJMoa1102673
Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfovealneovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056. https://doi.org/ 10.1016/j.ophtha.2012.10.014
Global Trends in Retina Survey. Ed. by KA Rezaei, TW Stone. Chicago: American Society of Retina Specialists; 2015.
Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50:2376-2383. https://doi.org/10.1167/iovs.08-2017
Wai KM, Singh RP. Treat and extend dosing regimen with anti-vascular endothelial growth factor agents for neovascular agerelated macular degeneration. Am J Ophthalmic Clin Trails. 2018;1(1):1-6. https://doi.org/10.25259/AJOCT-2-2018
Waldstein SM, Simander C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the view trials. Ophthalmology. 2016;123:1521-1529. https://doi.org/10.1016/j.ophtha.2016.03.037
Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120(9):1860-1870. https://doi.org/10.1016/j.ophtha.2013.01.073
Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(4):865-875. https://doi.org/10.1016/j.ophtha.2015.12.002
Waldstein SM. Wright J, Warburton J, et al. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123:60-69. https://doi.org/10.1016/j.ophtha.2015.09.013
Schmidt-Erfurth U, et al. Efficacy and safety of monthly versus quarterly ranibizumab Treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831-839. https://doi.org/10.1016/j.ophtha.2010.09.004
Schmidt-Erfurth U, Klimscha S, Waldstein SM, et al. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye. 2017;31:26-44. https://doi.org/10.1038/eye.2016.227
Guymer RH, Markey CM, McAllister IL, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab Using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126(5):723-734. https://doi.org/10.1016/j.ophtha.2018.11.025

Close metadata